Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions.
Good value with adequate balance sheet.
Share Price & News
How has Getinge's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GTN has not had significant price volatility in the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: GTN exceeded the German Medical Equipment industry which returned 22.5% over the past year.
Return vs Market: GTN exceeded the German Market which returned 3.8% over the past year.
Price Volatility Vs. Market
How volatile is Getinge's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Getinge undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GTN (€20.42) is trading below our estimate of fair value (€30.37)
Significantly Below Fair Value: GTN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GTN is good value based on its PE Ratio (30.4x) compared to the DE Medical Equipment industry average (52.3x).
PE vs Market: GTN is poor value based on its PE Ratio (30.4x) compared to the German market (20.9x).
Price to Earnings Growth Ratio
PEG Ratio: GTN is poor value based on its PEG Ratio (6.7x)
Price to Book Ratio
PB vs Industry: GTN is good value based on its PB Ratio (2.7x) compared to the DE Medical Equipment industry average (5x).
How is Getinge forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GTN's forecast earnings growth (4.5% per year) is above the savings rate (0.2%).
Earnings vs Market: GTN's earnings (4.5% per year) are forecast to grow slower than the German market (23.4% per year).
High Growth Earnings: GTN's earnings are forecast to grow, but not significantly.
Revenue vs Market: GTN's revenue (2.2% per year) is forecast to grow slower than the German market (5.9% per year).
High Growth Revenue: GTN's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GTN's Return on Equity is forecast to be low in 3 years time (10.2%).
How has Getinge performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GTN has high quality earnings.
Growing Profit Margin: GTN became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GTN's earnings have declined by 16.1% per year over the past 5 years.
Accelerating Growth: GTN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GTN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.9%).
Return on Equity
High ROE: GTN's Return on Equity (8.9%) is considered low.
How is Getinge's financial position?
Financial Position Analysis
Short Term Liabilities: GTN's short term assets (SEK18.9B) exceed its short term liabilities (SEK2.0B).
Long Term Liabilities: GTN's short term assets (SEK18.9B) do not cover its long term liabilities (SEK26.0B).
Debt to Equity History and Analysis
Debt Level: GTN's debt to equity ratio (56.6%) is considered high.
Reducing Debt: GTN's debt to equity ratio has reduced from 114.1% to 56.6% over the past 5 years.
Debt Coverage: GTN's debt is well covered by operating cash flow (45.1%).
Interest Coverage: GTN's interest payments on its debt are well covered by EBIT (10.3x coverage).
What is Getinge current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GTN's dividend (0.71%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.25%).
High Dividend: GTN's dividend (0.71%) is low compared to the top 25% of dividend payers in the German market (3.83%).
Stability and Growth of Payments
Stable Dividend: GTN's dividend payments have been volatile in the past 10 years.
Growing Dividend: GTN's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (21.8%), GTN's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GTN's dividends in 3 years are forecast to be well covered by earnings (28.2% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mattias Perjos (48 yo)
Mr. Mattias Perjos has been the Chief Executive Officer and President at Getinge AB since March 27, 2017. Mr. Perjos serves as Chief Executive Officer at FlexLink Systems, Inc. Mr. Perjos has been the Dire ...
CEO Compensation Analysis
Compensation vs Market: Mattias's total compensation ($USD5.27M) is above average for companies of similar size in the German market ($USD3.70M).
Compensation vs Earnings: Mattias's compensation has been consistent with company performance over the past year.
|CEO, President & Director||3.42yrs||kr46.04m||0.013% |
|Chief Financial Officer||2.67yrs||no data||0.0048% |
|Head of Investor Relations||no data||no data||no data|
|Executive Vice President of Quality & Regulatory Compliance||4.58yrs||no data||0.0013% |
|General Counsel||no data||no data||no data|
|Executive Vice President of Communications & Brand Management||3.17yrs||no data||no data|
|Executive Vice President of Human Resources & Sustainability||3.58yrs||no data||0.00037% |
|Chief Technology Officer of Surgical Workflows||4.58yrs||no data||no data|
|Chief Commercial Officer||2.67yrs||no data||0.00037% |
|President of Acute Care Therapies||no data||no data||0.00040% |
|President of Surgical Workflows||1.75yrs||no data||0.00092% |
|Corporate Head of Sustainability||no data||no data||no data|
Experienced Management: GTN's management team is considered experienced (3.3 years average tenure).
|CEO, President & Director||3.42yrs||kr46.04m||0.013% |
|Independent Director||13.33yrs||kr852.00k||0.0044% |
|Vice Chairman of Board||0.58yr||kr684.00k||20.03% |
|Independent Director||6.58yrs||kr684.00k||0.0019% |
|Independent Director||10.33yrs||kr722.00k||0.0016% |
|Independent Director||3.42yrs||kr684.00k||0.00065% |
|Employee Representative Director||7.58yrs||no data||no data|
|Employee Representative Director||0.17yr||no data||no data|
|Independent Director||3.42yrs||kr722.00k||no data|
Experienced Board: GTN's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Getinge AB's company bio, employee growth, exchange listings and data sources
- Name: Getinge AB
- Ticker: GTN
- Exchange: DB
- Founded: 1904
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr57.143b
- Listing Market Cap: kr5.529b
- Shares outstanding: 272.37m
- Website: https://www.getinge.com
Number of Employees
- Getinge AB
- Lindholmspiren 7A
- Västra Götaland County
- 417 56
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GNGB.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||May 1993|
|GETI B||OM (OMX Nordic Exchange Stockholm)||Yes||Class B Shares||SE||SEK||May 1993|
|GTN||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||May 1993|
|0GZV||LSE (London Stock Exchange)||Yes||Class B Shares||GB||SEK||May 1993|
|GETIBS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||SEK||May 1993|
|GNGB.Y||OTCPK (Pink Sheets LLC)||UNSPONSORD ADR||US||USD||Oct 2008|
Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapi ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/02 21:22|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.